All documents in the system
- Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBnet consensus statement - 2014
- South African National Tuberculosis Management Guidelines - 2014
- Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis - 2013
- Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis - 2013
- Guidelines for the management of tuberculosis in children - 2013
- Guidelines for the management of tuberculosis, human immunodeficiency virus and sexually-transmitted infections in correctional facilities - 2013
- MDR, XDR, TDR tuberculosis: ominous progression - 2012
- Implementing Collaborative TB-HIV Activities: A Programmatic Guide - 2012
- DR-TB drugs under the microscope - 2011 March
- Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource- constrained settings - 2011
- Botswana TB/HIV Policy Guidelines - 2011
- Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 update - 2011
- The Global Plan to Stop TB - 2011
- Use of interferon-gamma release assays in support of TB diagnosis - 2011
- Treatment of Tuberculosis: Guidelines for National Programmes - 2010
- Guidelines for Tuberculosis Preventative Therapy among HIV individuals of South Africa - 2010
- Guidelines for Management of Drug-Resistant Tuberculosis in South Africa - 2010
- Latent Tuberculosis Infection: A Guide for Primary Health Care Providers - 2010
- Advocacy Strategy for Adoption and Dissemination on the Policy on TB Control in Health Care Facilities, Congregate Settings and Households: Recommended Actions at International and National Level - 2010
- Rapid Advice: Treatment of Tuberculosis in Children - 2010
- Review of the National Tuberculosis Programme in Ukraine - 2010
- Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection in United States - 2010
- Guidance for national tuberculosis and HIV programmes on the management of tuberculosis in HIV-infected children: Recommendations for a public health approach - 2010
- Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice - 2010
- Guidance on Ethics of Tuberculosis Prevention, Care and Control - 2010
- Desk-guide for diagnosis and management of TB in children - 2010
- Revised National Tuberculosis Control Programme DOTS-Plus Guidelines - 2010
- South African National Tuberculosis Management Guidelines - 2009
- Management of MDR-TB: A field guide - 2009
- A guide to Monitoring and Evaluation for Collaborative TB/HIV Activities - 2009
- Natural Ventilation for Infection Control in Health-Care Settings - 2009
- Monitoring and Evaluation Toolkit: HIV, TB and Malaria and Health Systems Strenghtening - 2009
- Environmental Controls for Tuberculosis : Basic Upper-Room Ultraviolet Germicidal Irradiation Guidelines for Healthcare Settings - 2009
- Policy on TB Control in Health Care Facilities, Congregate Settings and Households - 2009
- Guidelines for Surveillance of Drug Resistant in Tuberculosis - 2009
- Plan to Combat Extensively Drug-Resistance Tuberculosis: Recommendations of the Federal Task Force - 2009
- Pediatric Infectious Disease Referral Guidelines: Tuberculosis in Children - 2009
- Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis - 2009
- Management of Latent TB Infection in Children and Adolescents: A Handbook for the Primary Care Provider - 2009
- The National Tuberculosis Health Sector Strategic Plan for Ghana - 2009
- Guidelines on management of Leprosy and Tuberculosis in Kenya - 2009
- MOST for TB: Management and Organizational Sustainability Tool for National TB Control Programs - 2009
- Tuberculosis: Information for Health Care Providers - 2009
- National Framework For Joint HIV/TB Collaborative Activities - 2009
- Drug Resistant Tuberculosis Guidelines and Manual for Swaziland - 2008
- Implementing the WHO Stop TB Strategy: Handbook for National TB Control Programmes - 2008
- WHO/The Union Monograph on TB and Tobacco Control - 2008
- Surveillance of Communicable Diseases in European Union: Long Term Strategy - 2008
- Managing TB Medicines at the Primary Level - 2008
- Managing Pharmaceuticals and Commodities: A Guide for National Tuberculosis Programs - 2008
- Framework Action Plan to fight tuberculosis in European Union - 2008
- The National Infection Prevention and Control Policy for TB, MDRTB and XDRTB - 2007
- Tuberculosis Strategic Plan for South Africa 2007-2011 - 2007
- National Policy Guidelines for HIV/TB Collaborative Activities - 2007
- Tuberculosis Infection Control in the Era of Expanding HIV Care and Treatment: Addendum to WHO Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings - 2007
- Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care — WHO interim guidelines - 2007
- Tuberculosis Care and Control in Refugee and Displaced Populations: An Interagency Field Manual - 2007
- Best Practice for the Care of Patients with Tuberculosis: A Guide for Low-Income Countries - 2007
- Priorities for Bacteriology Services in Low-Income Countries - 2007
- Implementation of HIV/TB Collaborative Activities for Ghana: Technical Policy and Guidelines - 2007
- Guideline for the Clinical Management of TB and HIV Co-infection in Ghana - 2007
- Canadian Tuberculosis Standards - 2007
- Environmental Control Best Practices: Guidelines to Reduce TB Transmission in Homeless Shelters and Drop-In Centres - 2007
- Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC - 2006
- International Standards for Tuberculosis Control - 2006
- Guidelines for Implementing TB-HIV Collaborative Activities in Kenya: What health workers need to know - 2006
- Guidance for national tuberculosis programmes on the management of tuberculosis in children - 2006
- Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Healthcare Settings - 2005
- Technical and Operational Guidelines for Tuberculosis Control - 2005
- A Tuberculosis Guide for Specialist Physicians - 2004
- Stopping Tuberculosis in England: An action plan - 2004
- Guidelines for Implementing Collaborative TB and HIV Programme Activities - 2003
- Guidelines for Environmental Infection Control in Healthcare Facilities - 2003
- European framework to decrease the burden of TB/HIV - 2003
- Guidelines for the investigation and follow-up of individuals under medical surveillance for tuberculosis after arriving in Canada - 2003
- Guidelines for Tuberculosis Control in New Zealand - 2003
- Treatment of the Patient with TB: Guidelines for Collaborting with Community Physicians - 2003
- Guidelines for Workplace TB Control Activities - 2003
- Guidelines for the Treatment of Tuberculosis - 2002
- General Recommendations on Immunization - 2002
- Interventions for Tuberculosis Control and Elimination - 2002
- A Guide for Tuberculosis Treatment Supporters - 2002
- An Expanded DOTS Framework for TB - 2002
- Guidelines for initiating a school-based directly observed therapy program - 2002
- National Strategic Plan for TB Control in Australia - 2002
- Management, Control and Prevention of Tuberculosis Guidelines for Health Care Providers - 2002
- Guide for the Procurement of Anti-Tuberculosis Drugs - 2001
- Tuberculosis in the Workplace - 2001
- Good Practice in Legislation and Regulations for TB Control: An Indicator of Political Will - 2001
- Guidelines for Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection - 2000
- Technical Guide: Sputum Examination for Tuberculosis by Direct Microscopy in Low-Income Countries - 2000
- Pharmaceutical Management for Tuberculosis (PMTB) Assessment Manual - 2000
- Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings - 1999
- Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents - 1998
- Enforcement Procedures and Scheduling for Occupational Exposure to Tuberculosis - 1996
- Guidelines for Preventing the Transmission of Tuberculosis in Canadian Health Care Facilities and Other Institutional Settings - 1996
- Policy Guidelines for Collaborative TB and HIV Services for Injecting and Other Drug Users: An Integrated Approach
- Recommendations for the Screening and Prevention of TB in Patients with HIV and the Screening for HIV in TB Patients and thier Contacts
- Response by Medicines Control Council to letter by Global TB CAB on bedaquiline
- TB CAB Open Letter to Otsuka Re: Pharmacokinetic Studies, Paediatric Studies, and Compassionate Use of Delamanid
- TB CAB Open Letter to Janssen Pharmaceutical Companies of Johnson & Johnson Re: Pharmacokinetic Studies, Paediatric Studies, and Compassionate Use of Bedaquiline
- TB CAB Open Letter to the Food and Drug Administration Re: Crucial Regulatory Harmonization on Endpoints and Pharmacokinetic Studies for Tuberculosis Drug Development
- TB CAB Open Letter to the European Medicines Agency Re: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)
- Postdoctoral fellowship in TB diagnostic research
- Letter Re: Changes in the ART guidelines
- Memorandum Re: New criteria for initiating HIV-positive TB patients on lifelong antiretroviral therapy (ART) irrespective of CD4 count
- Round table discussion: Activist engagement and community involvement in TB research
- Janssen's Response to TB CAB Letter 12 June 2012 regarding Pharmacokinetic Studies, Paediatric Studies, and Compassionate Use of Bedaquiline
- Otsuka's Response to TB CAB Letter regarding Pharmacokinetic Studies, Paediatric Studies, and Compassionate Use of Delamanid
- EMA's response to TB CAB letter regarding conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)
- Termination of the use of streptomycin for re-treatment cases
- TAG: Aspiring to Zero Symposium
- Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study
- Treatment of tuberculosis: have we turned the corner?
- The 43rd Union World Conference on Lung Health will tackle issues from multidrug-resistant TB to tobacco control and raise the profile of lung disease
- MSF and TAG symposium: NGO and civil societies' role in sustainable approaches for scaling up DR-TB programmes
- AfroCAB concept note
- Advanced TB Diagnostic Research
- Presenting the European Forum for TB Innovation: innovative thinking in progressing towards TB elimination in Europe
- Call for video testimonies
- Former TB patients: effective community engagement and lessons learnt
- Advocacy Corner at Union World Conference
- 4th Union Asia Pacific Region Conference on Lung Health, conference brochure
- Community consultation: A Silent Crisis: Tuberculosis Drug Shortages in the U.S.
- Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis
- Approval of novel TB drug celebrated - with restraint
- Post-2015 tuberculosis strategies in a pre-2015 world
- TB Laboratory Biosafety Manual
- Community-based tuberculosis prevention and care: Why and how to get involved
- Same-day diagnosis and treatment of tuberculosis
- WHO and the future of disease control programmes
- TAG: Public comment, Re: Urgent recommendations to address and resolve ongoing shortages of tuberculosis drugs in the United States
- EMA's response to TB CAB letter regarding the filing of the drugs delamanid and bedaquiline for market approval.
- International childhood TB training course, South Africa, 30 September - 4 October, 2013
- Global week of action against EU’s FTAs, 9-15 April 2013
- Free Heartland TB Intensive course, San Antonio, Texas, May 7-10, 2013
- Press release: Condemned to death came to the Cabinet of Ministers
- MDR-TB webinar in Russian: Basics of MDR-TB Program Management, 14 – 30 May 2013
- TB CAB open letter to Indian Prime Minister on EU-India FTA
- TB CAB open letter to Indian Health Minister on EU-India FTA
- TAG, TB CAB, India CAB open letter Re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries
- Lal Path Lab Memo
- RNTCP Serology Ad
- Drug-resistant tuberculosis: time for visionary political leadership
- The Global Drug Facility and its role in the market for tuberculosis drugs
- Qiagen's response to the open letter sent by TAG, TB CAB and India CAB re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries
- TAG symposium: Cascades: Improving TB Care
- Antiretroviral therapy for prevention of HIV and TB: A promising intervention but not a panacea
- Open letter to Indian Prime Minister: Stop the TB drug stockouts
- Fact sheet on TB drug stockouts
- Civil society demonstration, Wednesday, June 26, 2013
- Zero TB Deaths: A Pipedream? - Part 1
- Zero TB Deaths: A Pipedream? - Part 2
- Civil Society Memorandum
- Open letter to Sanofi: Reduce rifapentine cost and increase research funding
- TAG, TB CAB, India CAB open letter to Immunoshop Re: Marketing and use of TB Platinum for active TB in India and high TB burden countries
- 44th Union World Conference on Lung Health will focus on “Shared air, safe air?”
- Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study
- Sentinel Project: Workshop on inclusion of children in TB surveys, Union Conference, October 31, 2013
- Media coverage, TB drug stockouts in India, 2013
- Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data
- 'I cry every day’: experiences of patients co-infected with HIV and multidrug-resistant tuberculosis
- TAG, TB CAB open letter to Sequella Re: Further research into sutezolid urgently needed for tuberculosis
- Promoting affordable and quality tuberculosis testing in India
- TAG, TB CAB open letter to Alere Re: Responsible marketing and access plans for Alere’s Determine TB-LAM antigen test for active TB
- Invitation - Stop TB Partnership event, 31 October, Paris, France
- Provisional agenda - Stop TB Partnership event, 31 October, Paris, France
- Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-ra
- Administering second-line antituberculous medications to children with multidrug-resistant tuberculosis: A qualitative study
- Demostration, Fix the patent laws, South Africa, October 17, 2013
- CRAG open letter to Sanofi: Request for an official Sanofi response before escalation
- TAG symposium “Cascades: Improving TB Care”: Welcome - Colleen Daniels, TAG
- TAG symposium “Cascades: Improving TB Care”: Three Epiphanies - Paul Farmer, Harvard Medical School & PIH
- TAG symposium “Cascades: Improving TB Care”: Learning from the HIV experience: Continuum of Care Initiative - Ken Castro, U.S. Centers for Disease Control and Prevention
- TAG symposium “Cascades: Improving TB Care”: Can zero TB deaths become a reality? Lessons from Tomsk, Russian Federation - Salmaan Keshavjee, Harvard Medical School & PIH
- TAG symposium “Cascades: Improving TB Care”: Know your epidemic - David Dowdy, Johns Hopkins University
- TAG symposium “Cascades: Improving TB Care”: Patient centered approaches to cure - Jigna Rao, Patient Advocate
- TAG symposium “Cascades: Improving TB Care”: New Drugs, New Regimens, New Opportunities for MDR-TB - Jen Cohn, MSF
- WHO's 2013 global report on tuberculosis: successes, threats, and opportunities
- TB CAB, CRAG, TAG open letter to Otsuka, Re: Urgent appeal to initiate delamanid compassionate use program
- PRIFTIN PRICE REDUCTION NOTICE
- Who Makes Money on Epidemics of HIV/AIDS and Tuberculosis in Ukraine
- Open letter to Sanofi: Appreciation for commitment by Sanofi U.S. to lower the price of rifapentine
- TB CAB, TAG open letter to Cepheid Re: GeneXpert machine and Xpert MTB/RIF cartridge pricing, extended warranties and business in Russia and the People’s Republic of China
- Improving the health of the tuberculosis drug pipeline
- Call for Nominations - GLI Core Group Membership
- TB CAB, TAG public comment on Guidance for industry on pulmonary tuberculosis: Developing drugs for treatment
- GCTA Application Form 2014: INDIVIDUAL MEMBERSHIP
- GCTA Application Form 2014: NON-INDIVIDUAL MEMBERSHIP
- GCTA Constituency Charter (October 2013)
- TB CAB, GRAG, TAG open letter to AstraZeneca Re: Request to ensure continued investment in tuberculosis
- Otsuka's response to TB CAB, CRAG, TAG open letter regarding delamanid compassionate use program
- Open letter to Otsuka: continued concerns about delamanid's accessibility
- AstraZeneca: Response to TB CAB, CRAG, TAG open letter
- Otsuka and The Union announce Global TB Research & Innovation Award
- World TB Day 2014: finding the missing 3 million
- Smoking increases risk of recurrence after successful antituberculosis treatment: a population-based study
- Standards for TB Care in India (STCI), 1st edition, 2014
- International Standards for TB care (ISTC) 3rd edition, 2014
- Engage! brochure
- Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates
- soniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial
- Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?
- Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
- November 2014 conference: Developing a rights-based approach to TB: Call for papers
- TB CAB open letter: Ensuring the fair administration of the Kochon Prize
- Guidelines for Management of Drug-Resistant Tuberculosis in South Africa
- Flier: Ancient enemy, modern imperative: A time for greater action against tuberculosis
- Invitation AIDS 2014 Melbourne - Networking Zone: Should HIV activists be speaking louder about TB?
- Developing a Rights-Based Approach to Prevention and Treatment of Tuberculosis in India
- CALL FOR PAPERS: Developing a Rights-Based Approach to TB
- How to hinder tuberculosis control: five easy steps
- Letter from community groups to regulators regarding bedaquiline phase III trial design
- Virtual scientific workshop
- Working towards an HIV vaccine
- Tuberculosis drug discovery: Lessons learned and future prospects
- A rough guide to spotting bad science
- Open letter to Janssen: Reducing the price of bedaquiline
- Open letter to Janssen: Reducing the price of bedaquiline
- Open letter to Janssen: Reducing the price of bedaquiline
- TB CAB, TAG open letter to Janssen regarding the FDA approval of bedaquiline
- Understanding barriers to rifapentine use in U.S. tuberculosis programs to inform pricing advocacy
- Janssen's response to open letter calling on the company to reduce the price of bedaquiline
- Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
- Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis
- Assessment of the novel T-cell activation marker—tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study
- EMA Response to letter dated 28 July 2014
- Union Letter from Civil Society
- Civil society severely concerned with the Union's scholarship programme for the 45th Union World Conference on Lung Health
- Civil society severely concerned with the Union's scholarship programme for the 45th Union World Conference on Lung Health
- Janssen's response to open letter calling on the company to reduce the price of bedaquiline
- Letter to regulators re STREAM design from Community
- EMA answer to letter to regulators re STREAM 26.9.2014
- NA Union RPT Poster 19Feb2014
- P Stoffels letter BDQ pricing
- Assessment of the novel T-cell activation marker—tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study
- Community Corner at Union 2014
- Social protection and tuberculosis control in 21 European countries, 1995—2012: a cross-national statistical modelling analysis
- #CoughUpTheTBMoney: Civil society calls for tripling of money for TB research
- Activists urge Otsuka to provide access to TB drug
- Otsuka action, press release in Japanese
- UChicago TB Conference Call for Papers
- Rights-Based Approach to TB - University of Chicago Center in Delhi - Concept Note
- Abstract: Tuberculosis Drug Discovery, Lessons Learned and Future
- Abstract: Working Towards an HIV Vaccine
- Flyer
- DR-TB patients, activists demand registering generic linezolid, 14.10.2014
- Medicines Control Council's answer to TB CAB open letter on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa.
- How a new funding model will shift allocations from the Global Fund to Fight AIDS, Tuberculosis and Malaria
- Global TB CAB Meeting Report Arlington, US 2011
- Global TB CAB Meeting Notes Union Kuala Lumpur 2012
- Global TB CAB Meeting Notes New Delhi 2013
- Global TB CAB Meeting Notes Union Paris 2013
- Global TB CAB Meeting Notes New York 2014
- Advocacy Strategy for Adoption
- Implementation of HIV/TB Collaborative Activities for Ghana: Technical Policy and Guidelines
- National Framework For Joint HIV/TB Collaborative Activities
- Surveillance of Communicable Diseases in European Union: Long Term Strategy
- Technical Guide: Sputum Examination for Tuberculosis by Direct Microscopy in Low-Income Countries
- MOST for TB: Management and Organizational Sustainability Tool for National TB Control Programs
- Stopping Tuberculosis in England: An action plan
- Technical and Operational Guidelines for Tuberculosis Control
- Global TB CAB ToR
- Valneva announces publication of first Phase II data of tuberculosis vaccine candidate formulated with IC31® adjuvant
- Tuberculosis in pregnancy: an estimate of the global burden of disease
- Open letter to South African Medical Schemes re: covering linezolid
- Open letter to South African Medical Schemes re: covering linezolid
- Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios
- Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
- Timing, rates, and causes of death in a large South African tuberculosis programme
- Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: A stepped-wedge cluster-randomized trial
- CRAG: A Protocol Review Companion for Activists
- Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations
- Multidrug-resistant tuberculosis around the world: what progress has been made?
- Drug-resistance mechanisms and tuberculosis drugs
- Shortening treatment of tuberculosis: lessons from fluoroquinolone trials
- Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review
- Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study
- Tuberculosis vaccines: Time for a global strategy
- TAG open letter to the Global Plan Development Task Force
- Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial
- Effect of diabetes on tuberculosis control in 13 countries with high tuberculosis: a modelling study
- Symposium: Re-inventing adherence: Patient-centered approaches to drug-resistant TB and HIV treatment
- Implementing a molecular test to diagnose pulmonary tuberculosis in Brazil: a case study
- Letter to The Union re TB Language
- Joint Partners Forum registration form
- Joint Partners Forum preliminary agenda
- 2015 EML process
- Call to action: Accelerate access to DR-TB drugs
- Tuberculosis diagnostics in 2015: Landscape, priorities, needs, and prospects
- Tuberculosis diagnostics in 2015: Landscape, priorities, needs, and prospects
- Call to action: Accelerate access to DR-TB drugs
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly random
- Briefing document: Treating drug-sensitive TB in India: Implementation of daily therapy with fixed-dose combinations
- Sputum culture conversion as a prognostic marker for endof-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies
- Scaling up multidrug-resistant tuberculosis care in China
- Transforming the diagnosis of tuberculosis: an editorial board member’s opinion at the 15th year of Expert Review of Molecular Diagnostics
- Innovations in tuberculosis diagnostics: Progress and translational challenges
- Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives
- ECDC: Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA
- Open Letter to WHO: Time to report preventive TB therapy for children
- Supplementary appendix
- Riga Declaration
- Newsletter: Childhood tuberculosis update
- Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculo
- Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study
- Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial
- The End TB Strategy: India can blaze the trail
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial
- TB CAB, TAG open letter to the Global Plan Development Task Force
- Support for extension of transitional period and waivers of least developed countries on TRIPS Agreement
- Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial
- Letter from TB community re: intellectual property rights to sutezolid
- WHO response: Recording and reporting of preventive TB therapy in children
- Open letter to WHO: Recording and reporting of preventive TB therapy in children
- Jim O’Neill sets out plan to overhaul the global antibiotics pipeline
- Treatment of drug-resistant TB with new and repurposed medications: A supplemental field guide for nurses
- The Trans-Pacific Partnership — is it bad for your health?
- The use of delamanid in the treatment of multidrug-resistant tuberculosis
- Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis
- International Standards for TB care (ISTC) 3rd edition, 2014
- The use of bedaquiline in the treatment of multidrug-resistant tuberculosis (2013)
- Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 update (2011)
- Treatment of Tuberculosis: Guidelines for National Programmes (2010)
- Management of MDR-TB: A field guide
- WHO/The Union Monograph on TB and Tobacco Control (2008)
- Tuberculosis Care and Control in Refugee and Displaced Populations: An Interagency Field Manual (2007)
- A Guide for Tuberculosis Treatment Supporters (2002)
- An Extended DOTS framework for Tuberculosis (2002)
- Botswana TB/HIV Policy Guidelines (2011)
- Tuberculosis: Information for Health Care Providers (2009)
- ECDC: Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA (2015)
- Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBnet consensus statement (2014)
- Management of contacts of MDR TB and XDR TB patients (2012)
- Guideline for the Clinical Management of TB and HIV Co-infection in Ghana (2007)
- Standards for TB Care in India (STCI), 1st edition, 2014 (2014)
- Revised National Tuberculosis Control Programme DOTS-Plus Guidelines (2010)
- Guidelines for the Clinical and Operational Management of Drug-Resistant Tuberculosis (2013)
- Management of Tuberculosis: A Guide to the Essentials of Good Practice (2010)
- Best Practice for the Care of Patients with Tuberculosis: A Guide for Low-Income Countries (2007)
- Priorities for Bacteriology Services in Low-Income Countries (2007)
- International Strategy for Tuberculosis Care (2006)
- Guide for the Procurement of Anti-Tuberculosis Drugs (2001)
- Guidelines for the management of Drug Resistant Tuberculosis in Kenya (2010)
- Guidelines on management of Leprosy and Tuberculosis in Kenya (2009)
- National Tuberculosis Management Guidelines (2014)
- Guidelines for the management of tuberculosis in children (2013)
- Guidelines for Management of Drug-Resistant Tuberculosis in South Africa (2013)
- Guidelines for the management of tuberculosis, human immunodeficiency virus and sexually-transmitted infections in correctional facilities (2013)
- South African National Tuberculosis Management Guidelines (2009)
- Drug Resistant Tuberculosis Management Guidelines (2008)
- Latent Tuberculosis Infection: A Guide for Primary Health Care Providers (2013)
- Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis (2013)
- Plan to Combat Extensively Drug-Resistance Tuberculosis: Recommendations of the Federal Task Force (2009)
- Managing TB Medicines at the Primary Level (2008)
- Managing Pharmaceuticals and Commodities: A Guide for National Tuberculosis Programs (2008)
- Treatment of the Patient with TB: Guidelines for Collaborating with Community Physicians (2003)
- Guidelines for the Treatment of Tuberculosis (2002)
- Guidelines for Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection (2000)
- Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents (1998)
- Enforcement Procedures and Scheduling for Occupational Exposure to Tuberculosis (1996)
- Roadmap for Childhood Tuberculosis (2013)
- Guidance for national tuberculosis and HIV programmes on the management of tuberculosis in HIV-infected children: Recommendations for a public health approach (2010)
- Rapid Advice: Treatment of Tuberculosis in Children (2010)
- Guidance for national tuberculosis programmes on the management of tuberculosis in children (2006)
- National Guidelines For The Management Of Tuberculosis In Children (2012)
- Investigation and control of tuberculosis incidents affecting children in congregate settings (2013)
- Desk-guide for diagnosis and management of TB in children (2010)
- Management of Latent Tuberculosis in Children and Adolescents: A Handbook for the Primary Care Provider (2009)
- Guidelines for Initiating a School-Based Directly Observed Therapy Program (2002)
- Guidelines on the management of latent tuberculosis infection (2014)
- The Global Plan to Stop TB (2011-2015)
- Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings (2011)
- Advocacy Strategy for Adoption and Dissemination on the Policy on TB Control in Health Care Facilities, Congregate Settings and Households (2010)
- Guidance on Ethics of Tuberculosis Prevention, Care and Control (2010)
- Natural Ventilation for Infection Control in Health-Care Settings (2009)
- Policy on TB Control in Health Care Facilities, Congregate Settings and Households (2009)
- Implementing the WHO Stop TB Strategy: Handbook for National TB Control Programmes (2008)
- Infection prevention and control of epidemic- and pandemic-prone acute respiratory diseases in health care — WHO interim guidelines (2007)
- Tuberculosis Infection Control in the Era of Expanding HIV Care and Treatment: Addendum to Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings (2007)
- Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings (2007)
- Guidelines for Workplace TB Control Activities (2003)
- Good Practice in Legislation and Regulations for TB Control: An Indicator of Political Will (2001)
- Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings (1999)
- Management, Control and Prevention of Tuberculosis Guidelines for Health Care Providers (2002)
- National Strategic Plan for TB Control in Australia (2002)
- Environmental Control Best Practices: Guidelines to Reduce TB Transmission in Homeless Shelters and Drop-In Centres (2007)
- Framework Action Plan to fight tuberculosis in European Union (2008)
- European framework to decrease the burden of TB/HIV (2003)
- The National Tuberculosis Health Sector Strategic Plan for Ghana (2009-2013)
- Technical and Operational Guidelines for Tuberculosis Control (2005)
- Interventions for Tuberculosis Control and Elimination (2002)
- Guidelines for Tuberculosis Control in New Zealand (2003)
- National Strategic Plan on HIV, STIs and TB 2012-2016 (2012)
- Guidelines for Tuberculosis Preventative Therapy among HIV individuals of South Africa (2010)
- Tuberculosis Strategic Plan for South Africa 2007-2011 (2007)
- The National Infection Prevention and Control Policy for TB, MDRTB and XDRTB (2007)
- Stopping Tuberculosis in England: An Action Plan (2004)
- Latent Tuberculosis Infection: A Guide for Primary Health Care Providers (2010)
- MOST for TB: Management and Organizational Sustainability Tool for National TB Control Programs (2009)
- Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC (2006)
- Guidelines on Preventing the Transmission of Mycobacterium tuberculosis in Healthcare Settings (2005)
- Guidelines on Environmental Infection Control in Healthcare Facilities (2003)
- General Recommendations on Immunization (2002)
- Tuberculosis in the Workplace (2001)
- Xpert MTB/RIF implementation manual (2014)
- Policy update: Xpert MTB/RIF assay for the diagnosis of pulmonary and extra-pulmonary TB in adults and children (2013)
- Rapid Implementation of Xpert MTB/RIF diagnostic test (2011)
- Policy statement: Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle- income countries (2011)
- Use of interferon-gamma release assays in support of TB diagnosis (2011)
- Technical Guide: Sputum Examination for Tuberculosis by Direct Microscopy in Low-Income Countries (2000)
- Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection in United States (2010)
- Updated Guidelines for the Use of Nucleic Acid Ampflication Test in the Diagnosis of Tuberculosis (2009)
- A Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities (2009)
- Guidelines for Surveillance of Drug Resistance in Tuberculosis (2009)
- Guidelines for the Investigation and Follow-up of Individuals Under Medical Surveillance for Tuberculosis After Arriving in Canada (2003)
- Review of the National Tuberculosis Programme in Ukraine (2010)
- Surveillance of Communicable Diseases in European Union: Long Term Strategy (2008)
- Monitoring and Evaluation Toolkit: HIV, TB and Malaria and Health Systems Strenghtening (2009)
- Pharmaceutical Management for Tuberculosis (PMTB) Assessment Manual (2005)
- Policy Guidelines for Collaborative TB and HIV Services for Injecting and Other Drug Users (2008)
- Guidelines for Implementing Collaborative TB and HIV Programme Activities (2003)
- Recommendations for the Screening and Prevention of TB in Patients with HIV and the Screening for HIV in TB Patients and thier Contacts (2002)
- Implementation of HIV/TB Collaborative Activities for Ghana: Technical Policy and Guidelines (2007)
- National Framework For Joint HIV/TB Collaborative Activities (2009)
- Implementing Collaborative TB-HIV Activities: a Programmatic Guide (2012)
- Guidelines for Implementing TB-HIV Collaborative Activities in Kenya: What health workers need to know (2006)
- National Policy Guidelines for HIV/TB Collaborative Activities (2007)
- Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis (2013)
- Guidelines for surveillance of drug resistance in tuberculosis (2015)
- GUlf States
- FLYER: TAG symposium: Scale Up to Get Down to Zero TB deaths, new infections, and suffering
- Johns Hopkins response re: intellectual property rights to sutezolid
- Report of the Joint TB Monitoring Mission, India, 2015
- Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study
- Letter to President TB National Action Plan
- India: As healthcare workers die of TB - physicians, health organisations, TB groups, public health experts, and associations of healthcare workers - call for urgent action
- Postdoctoral fellowship in tuberculosis diagnostic research
- Sample File 3
- Prioritizing human rights in the Global Plan to Stop TB 2016-2020
- Research in diagnostics for tuberculosis: fundamentals, best practices, and priorities
- Appeal to develop VXc-486 for tuberculosis
- TB case detection in India: Urgent need to scale up Rapid TB Test Machines and cartridges
- Chao Center Reacquires Rights to Cycloserine
- Urgent need to scale up access to new treatment options for MDR-TB in the Philippines
- WHO: Checklist for periodic evaluation of TB infection control in health-care facilities
- Open letter to the Board and Executive Director of the Global Fund
- Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries
- Janssen letter to TB CAB re. compassionate use
- CSO letter ldc extension
- bedaquiline
- linezolid
- rifapentine
- delamanid
- Newest MDR-TB drug prices could fall by up to 95% through generic production
- Essential medicines are still essential
- Patient support interventions to improve adherence to drug-resistant tuberculosis treatment: A counselling toolkit
- Treatment Action Group response letter from Sandoz 29 October 2015
- WHO publication: Active tuberculosis drug-safety monitoring and management (aDSM)
- New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
- TB CAB Meeting Report_May2015_NYC_External
- Global Action Framework for TB Research
- Research for TB Elimination team
- GeneXpert TB test
- GeneXpert TB test free
- Call to action on addressing TB in women living with HIV
- Urgent need to register quality generic versions of linezolid in South Africa
- Annex 1
- Annex 2
- Annex 3
- GCTA launch of the Time for TB campaign
- Data for action: collection and use of local data to end tuberculosis
- Turning off the tap
- Controlling the seedbeds of tuberculosis
- Stopping tuberculosis
- Tuberculosis—getting to zero
- Stopping the body count
- No one with HIV should die from tuberculosis
- How can we reduce the global burden of disease
- Association between spending on social protection and tuberculosis burden: a global analysis
- Call for applications to vacant position on the Core Group of the Global Drug-resistant TB Initiative
- Open letter to Glenmark regarding registration and pricing of linezolid in South Africa
- Open letter to Hetero and Sanofi regarding pricing of linezolid in South Africa
- Open letter to Macleods regarding registration and pricing of linezolid in South Africa
- Open letter to Pfizer regarding pricing and availability of linezolid in South Africa
- Open letter to Teva regarding registration and pricing of linezolid in South Africa
- Open letter to Alkem regarding registration and pricing of linezolid in South Africa
- Open letter to Amneal regarding registration and pricing of linezolid in South Africa
- Open letter to Apotex regarding registration and pricing of linezolid in South Africa
- Access to effective antimicrobials: a worldwide challenge
- Understanding the mechanisms and drivers of antimicrobial resistance
- Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries
- Antibiotics: achieving the balance between access and excess
- Animal production and antimicrobial resistance in the clinic
- National action for global gains in antimicrobial resistance
- Exploring the evidence base for national and regional policy interventions to combat resistance
- International cooperation to improve access to and sustain effectiveness of antimicrobials
- NICE guideline on TB treatment and prevention (2016)
- Field Implementation Coordinator
- Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study
- Using existing data to illustrate—and close—the gap in access to new anti-tuberculosis drugs
- U.S. Senators appeal to President Obama for TB plan funding
- Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study
- The tuberculosis emergency in eastern Europe
- TORs U-CAP
- Inclusion of rifapentine in the Global Drug Facility catalogue
- GLI Core Group: Call for applications
- Update on the use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis
- Labor-HHS-Education Subcommittee
- Defense Subcommittee
- Labor-HHS-Education Subcommittee House
- Labor-HHS-Education Subcommittee Senate
- Subcommittee on State, Foreign Operations
- Subcommittee on State, Foreign Operations 2
- Labor-HHS-Education Subcommittee
- Consolidated guidelines: Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs
- Consultant post for the TB/HIV and community engagement unit of Global TB Programme of WHO
- LAM RSA letter from community
- U.S. Preventive Services Task Force issues draft recommendation statement on screening for latent tuberculosis infection
- Handbook on TB laboratory diagnostic methods for the European Union
- Changing the game for multidrug-resistant tuberculosis
- Why are people living with HIV still dying of tuberculosis?
- A breakthrough urine-based diagnostic test for HIV-associated tuberculosis
- WHO Civil Society Task Force on TB
- Unmask Stigma
- Public health and international drug policy
- Eye examination for early diagnosis of disseminated tuberculosis in patients with AIDS
- A blood RNA signature for tuberculosis disease risk
- Predicting active tuberculosis progression by RNA analysis
- Tackling tuberculosis in migrants
- Prevalence of and risk factors for active tuberculosis in migrants screened before entry to the UK
- Advocates call for WHO to update Delamanid Guidance to include children
- Advocates, alarmed by appalling global response to MDR-TB outbreak in Papua New Guinea, call on international agencies to take action
- Checklist
- National TB Programme of PNG for MDR-TB
- WHO joint response
- Webinar: Affordability and access to medicines
- Agenda
- World Health Organization recommends shorter treatment for multidrug-resistant TB
- Jim O’Neill presents final international recommendations for the world to defeat superbugs
- Introduction of new drugs and drug regimens for the management of drug-resistant tuberculosis in South Africa: policy framework version 1.1
- WHO treatment guidelines for drug-resistant tuberculosis: 2016 update (2016)
- TB CAB meeting report, Barcelona 2014
- TB CAB meeting report, Cape Town 2015
- Advocates commend Johns Hopkins University for pursuing a public health driven path for sutezolid’s development
- Call for Applications for CSO/CBO/patient representatives to serve on rGLC WHO Western Pacific Region
- TB HIV Networking Zone
- Enhancing the role of pharmacists in the cascade of tuberculosis care
- TB Treatment Trials Grid 2016
- Vacancy: Consultant post for the TB/HIV and community engagement unit of Global TB Programme of WHO
- Civil Society and Communities Declaration to End HIV: Human Rights Must Come First
- Guidelines for the examination of patent applications relating to pharmaceuticals
- WHO recommendations on shorter treatment of multidrug-resistant tuberculosis
- Call to Action to accelerate access to DR-TB drugs: 2016 update
- Advocates call for the Ministry of Health in Cote d’Ivoire to adopt new TB test - ENG
- Advocates call for the Ministry of Health in Cote d’Ivoire to adopt new TB test - french
- Prevalence of pulmonary tuberculosis in western China in 2010–11: a population-based, cross-sectional survey
- New challenges for tuberculosis control in China
- Activists call for withdrawal of substandard TB test from India
- Call for applications: Eastern Mediterranean Regional Green Light Committee
- STEP UP FOR TB - SIGN THE DOTTED LINE
- Stephen Lewis' keynote talk at TB 2016 in Durban
- Mike Frick's plenary talk at TB2016
- Mike Frick's plenary talk at TB2016 slides
- TB Alliance Stakeholders Association: Call for community representative
- PNG based job opportunities: TB clinicians for 2017
- Save the date: "Stop Double Standards" symposium on October 27, 2016
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible TB
- WHO policy guidance on the use of TB-LAMP for TB diagnosis
- Guidelines on extrapulmonary TB for India
- Advocates appeal to the Union Board to host Union World Conferences on Lung Health in high TB burden countries
- letter sent to Janssen
- letter sent to Otsuka
- The Union re: Hosting Union World Conferences on Lung Health in high burden countries
- The Union: bid document
- "Stop Double Standards" symposium on October 27, 2016
- 2017 ARASA call for applications for Training of Trainers Program
- Desk-guide for diagnosis and management of TB in children (2016)
- Otsuka response 10 October 2016
- Call for applications: TB R&D media training
- Advocates call for the Ministry of Health in Peru to facilitate access to delamanid, english
- Advocates call for the Ministry of Health in Peru to facilitate access to delamanid, spanish
- Primer on TB
- New TB compound to be developed for Pan-TB regimen
- Call to action
- Participants list
- TB changing flyer
- Letter Janssen
- Civil society statement following the 47th Union World Conference on Lung Health, Liverpool
- Urgent action required to end bureaucratic delays and expedite enrollment of the NExT study
- Advocates encourage the establishment of an essential diagnostics list
- Location, location, location: tuberculosis services in highest burden countries
- ACT Asia-Pacific!
- WHO: The use of delamanid in the treatment of MRD-TB in children and adolescents: Interim policy guidance
- Open letter EATG 24 October 2016 - EDL
- MSF open letter Global Fund
- WHO: Technical assistance for the strengthening of childhood TB case finding and management in Liberia
- Civil society statement on medicines regulation
- A coalition of Indian activists delivered a statement at the 6th Meeting of the BRICS Health Ministers in New Delhi, 15–16 December 2016
- Indian activists
- Symposium: Drug-resistant TB: challenges & opportunities
- Letter to BRICS Ministers through Health Secretaries
- Action Plan to address HIV and TB funding withdrawals in middle income countries
- Open letter to Johnson & Johnson on ensuring widespread access to bedaquiline for the treatment of tuberculosis
- Advocates call for the Philippines Food and Drug Administration to register delamanid
- Advocates encourage prioritization of drug-resistant TB research
- Advocates call on the Indian Prime Minister to ensure availability of new TB drugs to combat drug-resistant TB
- Advocates encourage Danaher to continue investments in Cepheid’s TB products
- Essential medicines for universal health coverage
- Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis
- Time to review treatment of isoniazid-resistant tuberculosis?
- Safety and efficacy of the C-Tb skin test to diagnose TB
- Advocates maintain pressure on the Ministry of Health to facilitate access to delamanid in Peru
- Advocates maintain pressure on the Ministry of Health to facilitate access to delamanid in Peru (spanish)
- Call for applications: GCTA Regional Focal Points
- India plans to expand access to new TB drug
- Advocates call on Sequella to provide open access to sutezolid data
- Webinar on TB diagnostics
- Advocates call on PEPFAR to roll out LAM test
- Urgent need to roll out LAM test for TB in some people with HIV
- Damien Foundation Letter
- Danaher response
- GLI Core Group: Call for applications
- Advocates encourage the health authorities in Peru to approve the endTB study
- Application form
- Terms of reference
- DR-TB STAT on WHO bedaquiline recommendations
- Cepheid
- New plan to end tuberculosis in south and southeast Asia
- Reducing global tuberculosis deaths—time for India to step up
- Sustaining tuberculosis decline in the UK
- Candle Light Vigil held at India Gate in memory of the lives lost to TB
- Liverpool TB CAB meeting 2016
- Durban TB CAB meeting 2016
- Guidelines for treatment of drug-susceptible tuberculosis and patient care
- webinars
- workshop
- Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis
- TB Treatment Trials Grid 2017
- Delamanid letter
- Regional capacity-building workshop for TB survivors, English
- Regional capacity-building workshop for TB survivors, Spanish
- Who pays for cooperation in global health?
- Letter: Advocates call on Kenyan DLTLD to adopt new TB test
- TB CAB position paper XDR-TB
- Vacancy: TB Advocacy Officer, MSF Access Campaign
- Bedaquiline or delamanid for rifampin-resistant tuberculosis?
- memo tb
- Advocates call on Indian authorities to ensure immediate access to delamanid
- Symposium: Reframing risk and accountability for action to zero TB
- Job profile
- Report: TB medicine crisis in Romania
- Mileni letter
- Letter english
- letter spanish
- Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis
- letter president Kenya
- letter CS Kenya
- letter India MoH
- position paper Kenya
- Erica's talk
- Romania open letter
- flyerf TB course
- Submission form eng
- Submission form ru
- Copyright eng
- Copyright ru
- open letter TB WHO
- Kenya diagnostics
- tedros response
- kenya dr tedros
- WHO position statement on the use of delamanid for multidrug-resistant tuberculosis
- Handbook for the use of digital technologies to support tuberculosis medication adherence
- letter who guidelines
- GeneXpert Omni factsheet
- TB CAB position paper bedaquiline
- letter who guidelines 07.02.2018
- letter who guidelines 20.02.2018
- Latent TB Infection: Updated and consolidated guidelines for programmatic management
- vaccine
- WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis (2018)
- GFAN World TB Day Communications Toolkit
- Advocates call on Commissioner Andriukaitis to foster EU member states’ response to TB
- GLI Core Group: Call for applications
- Advocates call on PEPFAR to ensure TB-LAM testing in 2018 COPs
- lam pepfar
- Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary results
- letter who
- GDI Core Group: Call for applications
- Advocates call for urgent reforms of WHO TB diagnosis and treatment guidelines
- Key Asks from TB Stakeholders and Communities Russian
- Key Asks from TB Stakeholders and Communities Spanish
- Global governance of antimicrobial resistance
- UNAIDS side lunch event during the Interactive Civil Society Hearing on TB
- Factsheet on TB diagnostics development
- Advocates call on Indian Prime Minister to attend the UN High-Level Meeting on TB
- Human rights letter
- Towards the 2018 UN High-Level Meeting on TB: Recommendations by German civil society organizations
- Women & Stigma: Conversations of Resilience in the War Against TB
- 5th South African TB Conference, Conference closing session: Closing Remarks by Minister of Health, 15 June 2018
- UN HLM on TB Key Ask 1: 40 million by 2022
- New bedaquiline data shows reduction in TB mortality cases
- Global TB CAB welcomes introduction of safer drug for most South Africans with rifampicin-resistant TB
- Special Rapporteur on the Right to Health letter
- TB isolation policy
- letter Indian Minister of Health
- SIRTURO registration
- template letter
- recommendations
- letter page 1
- letter page 2
- Common African Position on the UN High-Level Meeting on TB
- Outcome document of the United Nations meeting on tuberculosis at risk. Germany must not give in to pressure from the US government under Trump
- 106 members of U.S. Congress sign letter supporting the UN High-Level Meeting on TB
- The TB CAB and TAG welcome WHO recommendation of injectable-free regimens for the treatment of RR/MDR-TB
- Urgent need to register essential medicines for the treatment and prevention of TB in South Africa
- Handbook on TB laboratory diagnostic methods in the European Union – updated 2018
- Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) (2018)
- Better and safer treatment for multidrug-resistant TB
- HLM Country Statement Checklist
- template cover letter
- Civil society and affected communities respond to WHO's Global TB Report 2018
- UN High-Level Meeting to end tuberculosis disappointing
- Advancing global tuberculosis control after the UNGA-HLM
- Activists: Call on your countries to use bedaquiline-based regimens to treat TB
- WHO and FIND: Technical guide on sequencing
- Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children (2018)
- Advocates call on Otsuka to reduce the price of delamanid
- Otsuka reply
- Rapid shift from global to national purchase of TB drugs increases risk of stockouts and use of drugs of unknown quality
- Rapid shift from global to national purchase of TB drugs increases risk of stockouts and use of drugs of unknown quality
- Activists call on countries and donors to immediately scale up use of life-saving TB LAM test
- Activists urge National TB Programs and treatment providers to discontinue use of harmful injectable agents in TB treatment
- Field guide for the management of drug-resistant tuberculosis (2018)
- Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis (2018)
- Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment
- Urgent need to address the Global Fund procurement cliff for TB
- handout
- Call for applications: Steering committee - Declaration on the Rights of People with TB
- Call for proposals: Community Representative Grant for TB Drug R&D
- Global burden of TB: where we are and what to do
- Advocates call on Kenyan government to immediately address dangerous stock out of diagnostic tests for TB
- Advocates call on Indian government to improve its response to drug-resistant TB
- After the UNGA High-Level Meeting on TB — what next and how?
- WHO consolidated guidelines on drug-resistant tuberculosis treatment
- WHO guidelines on TB infection prevention and control
- Building an Evidence Base to Advocate for TB Research
- Call for case studies and good practices on action on TB and comorbidities
- Building an Evidence Base to Advocate for TB Research 2
- TB CAB statement on M72/AS01E TB vaccine candidate
- WHO Platform for community-based TB activities releases its first newsletter
- Advocates raise serious concerns about errors in the WHO guidelines for the treatment of drug-resistant TB
- Ad-hoc donations of bedaquiline threaten sustainable, affordable access for patients
- Call for applications: Consultant to support the WHO Global TB Program Secretariat of the Civil Society Task Force on TB
- WHO response
- Research, regulatory, and access considerations regarding pretomanid
- Tuberculosis: Seminar
- Crisis of confidence in the WHO's ability to produce normative guidance for the treatment of RR-/MDR-TB
- TAG testimony
- TB CAB testimony
- NTCA
- dr Furin testimony
- letter tb alliance
- BHIVA guidelines
- Management of active tuberculosis in adults with HIV
- Transparency and access to pretomanid and the Nix-TB regimen
- Practice-based recommendations for the management of RR/MDR-TB
- South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection
- Webinar: Advancements in TB diagnostics
- Call for members: Community Delegation to the Stop TB Partnership Board
- Call for members: Developing Country NGO Delegation to the Stop TB Partnership Board
- Call for members: Developed Country NGO Delegation to the Stop TB Partnership Board
- Time to lower the price of Xpert cartridges to US$ 5
- CIVIL SOCIETY DEMANDS AFFORDABILITY, TRANSPARENCY AND ACCOUNTABILITY FROM THE TB ALLIANCE
- information note
- Civil society statement on rifapentine price discount
- Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV
- Time to lower the price of Xpert cartridges to US$ 5
- ATS, CDC, ERS and IDSA publish new clinical guideline for the treatment and prevention of drug-resistant TB
- Multidrug-resistant tuberculosis in children and adolescents in the WHO European Region
- TB Alliance, response, pretomanid
- Developed Country NGO BM & ABM Call for Nominations 2019
- Open Letter to Cepheid - Time to Lower the Price of Xpert Cartridges to US$5 - 6 Jan 2020
- press release g-finder 2019
- terms of reference
- Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
- Rapid Communication on forthcoming changes to the programmatic management of tuberculosis preventive treatment
- Letter Cepheid - TAG_April 4 2020
- Civil society call for equitable and affordable access to COVID-19 and related diagnostics
- RCC-THV: Call to action in response to COVID-19
- TB CAB Statement
- Rapid diagnostics for TB detection
- Rapid diagnostics for TB detection, handbook
- Drug-resistant TB treatment
- Drug-resistant TB treatment, handbook
- Applications for Community Connect Track Leads
- Declaration of the Rights of People Affected by TB, Arabic
- TBpeople: Vacancy assistant position
- The European Investment Bank provides €30 million loan to accelerate TB vaccine development
- TB affected community & civil society priorities for new Global AIDS Strategy
- Cepheid Xpert MTB/RIF Communication September 2011
- who instruction
- Tuberculosis and COVID-19: an overview of two health emergencies
- 2021-2024 TB CAB Membership Application
- Letter to NACO CTD for TPT in India
- Advocates request Cepheid increase access to GeneXpert SARS-CoV-2 tests in LMICs
- TBWomen launch
- Screening guidelines
- TAG response_March2021
- OPEN LETTER- Urgent appeal to improve access to GeneXpert and other diagnostics
- TPT Fundamentals for Activists - Flyer 2021
- WHO operational handbook on tuberculosis, Module 2: Screening - Systematic screening for tuberculosis disease (2021)
- Psychosocial counselling and treatment adherence support for people affected by tuberculosis
- Guidance for the surveillance of drug resistance in tuberculosis: Sixth edition
- CSO_Response_2021.05.21
- Vacancy: STBP Affected Communities Delegation - Advocacy Officer
- Call for applications: Constituency Focal Point for the Developed Country NGO Delegation to Global Fund Board
- Call for applications: Short Term Consultancy with GCTA
- Time for $5 Coalition open letter
- Treatment of drug-susceptible tuberculosis: rapid communication
- Community engagement lessons learned: A community perspective
- WHO operational handbook on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection 2021 update
- WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection 2021 update
- Advocates ring the alarm on TB medicines and diagnostics stock outs across India
- International support for compulsory license to address access barriers to life-saving TB medicines
- Advocates urge Cepheid to reinstate plans to commercialize GeneXpert Omni
- Stop TB Partnership: Official side-event at Tokyo Nutrition for Growth Summit 2021
- Global launch of Learnings, Best Practices and Challenges on TB Stigma, Discrimination and Human Rights report
- Advocates call on Unitaid to prioritise AIDS deaths and TB treatment in its investment and strategic plans
- The journey continues
- Advocates call on Indian government to stop using injectable agents for the treatment of drug-resistant TB
- Social Justice & the TB Epidemic: It is time to invest in human rights
- Advocates demand immediate national roll out of 3HP in India
- The Lancet: Growing concern over Ukrainian refugee health
- The Lancet: Seeking accountablity for Ukraine health-care attacks
- Invest in women to end TB – Where women lead, change happens
- Table
- DS-TB WHO guidelines
- DS-TB WHO handbook
- WHO guidelines pediatrics
- WHO handbook pediatrics
- Manual for selection of molecular WHO recommended rapid diagnostic tests for detection of TB and DR-TB
- Practical manual of processing stool samples for diagnosis of childhood TB
- Line probe assays for detection of DR-TB
- TB legislation ENG
- TB legislation RU
- Joint statement
- Forum invitation
- Cocept note
- Declaration of the Rights of People Affected by TB
- Indian letter
- TB care and support, guidelines
- TB care and support, handbook
- TB CAB 10-year anniversary evaluation report 2011–2021
- Advocates reiterate its demand for immediate national roll out of 3HP in India
- WHO operational handbook on tuberculosis. Module 3: Diagnosis - Tests for tuberculosis infection
- WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis – Tests for tuberculosis infection
- Updates required to the National TB guidelines to support access to shorter regimens as a human right in India
- 1/4/6x24 Campaign call to action at the USAID TB Symposium
- Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health
- Manual on selection and use of interferon-gamma release assays (IGRAs) for testing for TB infection
- WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
- WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
- Manual on selection and use of interferon-gamma release assays (IGRAs) for testing for TB infection (2022)
- Urgent action necessary to improve equitable access to bedaquiline-based regiments and achieve 1/4/6×24
- Practical manual on laboratory strengthening (2022)
- Webinar: What's new in childhood TB
- Priority TB community, rights & gender interventions for inclusion in Global Fund applications 2023-2025
- Diagnosis and Management of Tuberculosis in Children and Adolescents: A Desk Guide for Primary Health Care Workers - Asia (2023)
- Diagnosis and Management of Tuberculosis in Children and Adolescents: A Desk Guide for Primary Health Care Workers - Africa (2023)
- Urgent action necessary to improve equitable access to GeneXpert TB diagnostics and achieve 1/4/6x24
- ECDC-WHO/Europe World TB Day webinar
- Fast-tracking progress to End TB: high-level opportunities for investment and action
- Joint statement
- Call to action
- Newsletter
- flyer
- Vax CAB 2023 roadmap
- Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note (2023)
- Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information note (2023)
- Urgent action necessary for equitable access to bedaquiline in all countries with high burdens of TB, MDR-TB, and TB/HIV
- Member States must commit to invest in TB vaccine R&D
- Open letter to Johnson & Johnson requesting clarification on the recent deal on generic bedaquiline supply
- WHO operational handbook on tuberculosis: module 1: prevention: infection prevention and control
- WHO consolidated guidelines on tuberculosis: Module 1: Prevention - infection prevention and control
- webinar
- flyer survey
- Webinar: Time for $5 Campaign update